Therapeutic response was evaluated using breast cancer in vitro assays and GDSC drug sensitivity data.<h4>Results</h4>FKBP10 was significantly upregulated in multiple cancers, especially breast and renal carcinoma, and strongly associated with poor prognosis. Here, FKBP10 is linked to breast cancer.